{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:37:04Z","timestamp":1791023824018,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.canrad.2011.02.003","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T13:19:20Z","timestamp":1309007960000},"page":"316-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ciblage pharmacologique de Mdm2\u00a0: bases biologiques et perspectives de radiosensibilisation"],"prefix":"10.1016","volume":"15","author":[{"given":"C.","family":"Chargari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Deberne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2011.02.003_bib0005","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canrad.2011.02.003_bib0010","first-page":"81","article-title":"p53\u00a0and human cancer: the first 10,000\u00a0mutations","volume":"77","author":"Hainaut","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53\u00a0network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2011.02.003_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0025","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53\u00a0interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1278-3218(97)89592-3","article-title":"Modulation de la r\u00e9ponse cellulaire aux radiations ionisantes vers de nouvelles cibles mol\u00e9culaires\u00a0?","volume":"1","author":"Verrelle","year":"1997","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2011.02.003_bib0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A single nucleotide polymorphism in the MDM2\u00a0promoter attenuates the p53\u00a0tumor suppressor pathway and accelerates tumor formation in humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2401619","article-title":"Incidence and prognostic significance of MDM2\u00a0oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia","volume":"14","author":"Zhou","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.canrad.2011.02.003_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568009053332627","article-title":"MDM2\u00a0is a central node in the p53\u00a0pathway: 12\u00a0years and counting","volume":"5","author":"Bond","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.canrad.2011.02.003_bib0050","first-page":"2231","article-title":"p53\u00a0mutation and Mdm2\u00a0amplification in human soft tissue sarcomas","volume":"53","author":"Leach","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0055","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/bjc.1995.189","article-title":"Amplification of the MDM2\u00a0gene in human breast cancer and its association with MDM2\u00a0and p53\u00a0protein status","volume":"71","author":"McCann","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0959-8049(94)90128-7","article-title":"MDM2\u00a0gene amplification in human breast cancer","volume":"30","author":"Quesnel","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates Mdm2\u00a0mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canrad.2005.10.008","article-title":"Sarcomes des tissus mous\u00a0: donn\u00e9es mol\u00e9culaires actuelles","volume":"10","author":"Bui Nguyen Binh","year":"2006","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2011.02.003_bib0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53\u00a0function leads to tumour regression in vivo","volume":"445","author":"Ventura","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2011.02.003_bib0080","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53\u00a0restoration in tumors","volume":"127","author":"Martins","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0085","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53\u00a0restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2011.02.003_bib0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10495-009-0330-1","article-title":"Targeting p53\u00a0for enhanced radio- and chemo-sensitivity","volume":"14","author":"Lu","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.canrad.2011.02.003_bib0100","first-page":"2065","article-title":"Transfection with Mdm2-antisense or wtp53\u00a0results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line","volume":"21","author":"Gr\u00fcnbaum","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0105","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.274.5289.948","article-title":"Structure of the MDM2\u00a0oncoprotein bound to the p53\u00a0tumor suppressor transactivation domain","volume":"274","author":"Kussie","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canrad.2011.02.003_bib0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03402141","article-title":"Mdm2: the ups and downs","volume":"5","author":"Juven-Gershon","year":"1999","journal-title":"Mol Med"},{"key":"10.1016\/j.canrad.2011.02.003_bib0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2741\/A723","article-title":"Function and dysfunction of the human oncoprotein Mdm2","volume":"7","author":"Deb","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.canrad.2011.02.003_bib0120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jnci\/86.17.1265","article-title":"MDM2\u00a0and p53: a question of balance","volume":"86","author":"Meltzer","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2011.02.003_bib0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1568009053332618","article-title":"p53-independent activities of MDM2\u00a0and their relevance to cancer therapy","volume":"5","author":"Zhang","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.canrad.2011.02.003_bib0130","first-page":"1222","article-title":"The RING domain of Mdm2\u00a0can inhibit cell proliferation","volume":"62","author":"Dang","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcancer.2009.10.003","article-title":"Small-molecule inhibitors of MDM2\u00a0as new anticancer therapeutics","volume":"20","author":"Dickens","year":"2010","journal-title":"Seminute Cancer Biol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0140","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1101\/gad.11.6.714","article-title":"Targeted expression of MDM2\u00a0uncouples S phase from mitosis and inhibits mammary gland development independent of p53","volume":"11","author":"Lundgren","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0145","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1101\/gad.8.15.1739","article-title":"Regulation of Mdm2\u00a0expression by p53: alternative promoters produce transcripts with non identical translation potential","volume":"8","author":"Barak","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0150","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1101\/gad.886901","article-title":"ATM-dependent phosphorylation of Mdm2\u00a0on serine\u00a0395: role in p53\u00a0activation by DNA damage","volume":"15","author":"Maya","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0155","doi-asserted-by":"crossref","first-page":"18771","DOI":"10.1074\/jbc.M413387200","article-title":"Mdm2\u00a0binds to Nbs1\u00a0at sites of DNA damage and regulates double strand break repair","volume":"280","author":"Alt","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0160","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/01.cad.0000180116.85912.69","article-title":"Hypoxia inducible factor-1: a novel target for cancer therapy","volume":"16","author":"Belozerov","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canrad.2011.02.003_bib0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2\u00a0sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canrad.2011.02.003_bib0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0175","doi-asserted-by":"crossref","first-page":"53365","DOI":"10.1074\/jbc.M408554200","article-title":"Novel function of orphan nuclear receptor Nur77\u00a0in stabilizing hypoxia-inducible factor-1alpha","volume":"279","author":"Yoo","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0180","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1158\/0008-5472.CAN-03-3038","article-title":"Hypoxia enhances metastatic efficiency by up-regulating Mdm2\u00a0in KHT cells and increasing resistance to apoptosis","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0185","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jcp.20406","article-title":"Mdm2\u00a0and HIF-1alpha interaction in tumor cells during hypoxia","volume":"204","author":"Nieminen","year":"2005","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0190","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1128\/MCB.24.7.2905-2914.2004","article-title":"Growth factor-mediated induction of HDM2\u00a0positively regulates hypoxia-inducible factor 1alpha expression","volume":"24","author":"B\u00e1rdos","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0195","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.canrad.2009.07.007","article-title":"Th\u00e9rapies antiangiog\u00e9niques et radioth\u00e9rapie\u00a0: du concept \u00e0 l\u2019essai clinique","volume":"13","author":"Cohen-Jonathan Moyal","year":"2009","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2011.02.003_bib0200","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2174\/092986708784872375","article-title":"Small molecule inhibitors of the p53\u2013MDM2","volume":"15","author":"Hu","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cbpa.2008.04.603","article-title":"Small molecular weight protein\u2013protein interaction antagonists: an insurmountable challenge?","volume":"12","author":"Domling","year":"2008","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/sj.bjc.6604098","article-title":"Updates on p53: modulation of p53\u00a0degradation as a therapeutic approach","volume":"98","author":"Dey","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0215","first-page":"666","article-title":"Small-molecule inhibitors of protein\u2013protein interactions","volume":"11","author":"Berg","year":"2008","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0220","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bmcl.2004.11.009","article-title":"1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53\u00a0interaction: discovery and SAR","volume":"15","author":"Parks","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.canrad.2011.02.003_bib0225","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/anie.200462316","article-title":"Terphenyl-based helical mimetics that disrupt the p53\/HDM2\u00a0interaction","volume":"44","author":"Yin","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.canrad.2011.02.003_bib0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1535-7163.MCT-05-0199","article-title":"Benzodiazepinedione inhibitors of the Hdm2:p53\u00a0complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo","volume":"5","author":"Koblish","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2011.02.003_bib0235","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1021\/jm060023+","article-title":"Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53\u00a0interaction through an integrated, virtual database screening strategy","volume":"49","author":"Lu","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0240","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1535-7163.MCT-04-0342","article-title":"p53\u00a0alpha-Helix mimetics antagonize p53\/MDM2\u00a0interaction and activate p53","volume":"4","author":"Chen","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2011.02.003_bib0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/bi000930v","article-title":"Chalcone derivatives antagonize interactions between the human oncoprotein MDM2\u00a0and p53","volume":"40","author":"Stoll","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.canrad.2011.02.003_bib0250","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/jm034182u","article-title":"A non peptidic sulfonamide inhibits the p53-Mdm2\u00a0interaction and activ\u00e2tes p53-dependent transcription in Mdm2-overexpressing cells","volume":"47","author":"Galatin","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0255","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1101\/gad.8.10.1235","article-title":"Several hydrophobic amino acids in the p53\u00a0amino-terminal domain are required for transcriptional activation, binding to mdm-2\u00a0and the adenovirus\u00a05\u00a0E1B 55- kD protein","volume":"8","author":"Lin","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.canrad.2011.02.003_bib0260","first-page":"2141","article-title":"Identification of novel Mdm2\u00a0binding peptides by phage display","volume":"13","author":"Bottger","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.canrad.2011.02.003_bib0265","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-08-2955","article-title":"Restoration of p53\u00a0pathway by nutlin-3\u00a0induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells","volume":"15","author":"Miyachi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0270","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10495-010-0457-0","article-title":"Enhancement of imatinib-induced apoptosis of BCR\/ABL-expressing cells by nutlin-3\u00a0through synergistic activation of the mitochondrial apoptotic pathway","volume":"15","author":"Kurosu","year":"2010","journal-title":"Apoptosis"},{"key":"10.1016\/j.canrad.2011.02.003_bib0275","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/jnci\/djp355","article-title":"Antitumor activity of the selective MDM2\u00a0antagonist nutlin-3\u00a0against chemoresistant neuroblastoma with wild-type p53","volume":"101","author":"Van Maerken","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2011.02.003_bib0280","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bcp.2009.09.020","article-title":"DNA damage response to the Mdm2\u00a0inhibitor nutlin-3","volume":"79","author":"Verma","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0285","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1593\/neo.07523","article-title":"The MDM-2\u00a0antagonist nutlin-3\u00a0promotes the maturation of acute myeloid leukemic blasts","volume":"9","author":"Secchiero","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.canrad.2011.02.003_bib0290","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/0008-5472.CAN-06-2710","article-title":"Nutlin3\u00a0blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2","volume":"67","author":"LaRusch","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0295","doi-asserted-by":"crossref","first-page":"45643","DOI":"10.1074\/jbc.M404097200","article-title":"Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha. HDM2, and p70S6K1\u00a0in response to phosphatidylinositol 3-kinase\/AKT signaling","volume":"279","author":"Skinner","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0300","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1158\/1535-7163.MCT-05-0356","article-title":"Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2","volume":"5","author":"Cao","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2011.02.003_bib0305","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53\u00a0interaction","volume":"49","author":"Ding","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.canrad.2011.02.003_bib0310","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53\u00a0pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canrad.2011.02.003_bib0315","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53\u00a0by a specific MDM2\u00a0inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canrad.2011.02.003_bib0320","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1476-4598-8-115","article-title":"An MDM2\u00a0antagonist (MI-319) restores p53\u00a0functions and increases the life span of orally treated follicular lymphoma bearing animals","volume":"8","author":"Mohammad","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0325","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ejca.2010.01.015","article-title":"Mdm2\u00a0inhibitor MI-319\u00a0in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53\u00a0function","volume":"46","author":"Azmi","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0330","unstructured":"A study of RO5045337 [RG7112] in patients with advanced solid tumors (essai clinique). Informations disponibles \u00e0 l\u2019adresse\u00a0: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00559533 (acc\u00e8s le 21\/3\/11)."},{"key":"10.1016\/j.canrad.2011.02.003_bib0335","unstructured":"A study of RO5045337 [RG7112] in patients with hematologic neoplasms (essai clinique). Informations disponibles \u00e0 l\u2019adresse\u00a0: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00623870 (acc\u00e8s le 21\/3\/11)."},{"key":"10.1016\/j.canrad.2011.02.003_bib0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jgm.1424","article-title":"Inhibition of the p53-MDM2\u00a0interaction by Adenovirus delivery of ribosomal protein L23\u00a0stabilizes p53\u00a0and induces cell cycle arrest and apoptosis in gastric cancer","volume":"12","author":"Zhang","year":"2010","journal-title":"J Gene Med"},{"key":"10.1016\/j.canrad.2011.02.003_bib0345","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-peptide inhibitors of the p53-MDM2\u00a0interaction for targeted molecular therapy of malignant neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canrad.2011.02.003_bib0350","doi-asserted-by":"crossref","first-page":"14734","DOI":"10.1073\/pnas.212428599","article-title":"Differentiation of Hdm2-mediated p53\u00a0ubiquitination and Hdm2\u00a0autoubiquitination activity by small molecular weight inhibitors","volume":"99","author":"Lai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canrad.2011.02.003_bib0355","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1535-7163.MCT-10-0337","article-title":"The novel tryptamine derivative JNJ-26854165\u00a0induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias","volume":"9","author":"Kojima","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2011.02.003_bib0360","doi-asserted-by":"crossref","unstructured":"St\u00fchmer T, Arts J, King P, Page M, Bommert K, Leo E, et al. A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo. J Clin Oncol 2008;26 [ASCO meeting abstract 14\u00a0694].","DOI":"10.1200\/jco.2008.26.15_suppl.14694"},{"key":"10.1016\/j.canrad.2011.02.003_bib0365","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood.V112.11.3618.3618","article-title":"Inhibition of the human double minute (HDM)-2\u00a0E3\u00a0ubiquitin ligase activates different programmed cell death (PCD) pathways in models of non-hodgkin lymphoma (NHL) with wild type (wt) and mutant (mut) p53","volume":"112","author":"Jones","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2011.02.003_bib0370","unstructured":"Arts J, Page M, Valckx A, Blattner C, Kulikov R, Floren W, et al. JNJ-26854165 \u2013 a novel hdm2\u00a0antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies. AACR Meeting abstract, Apr 2008 [abst\u00a01592]."},{"key":"10.1016\/j.canrad.2011.02.003_bib0375","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1128\/MCB.16.5.2445","article-title":"Mdm2\u00a0inhibits the G1\u00a0arrest and apoptosis functions of the p53\u00a0tumor suppressor protein","volume":"16","author":"Chen","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.canrad.2011.02.003_bib0380","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2007.03.047","article-title":"Antisense-MDM2\u00a0sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo","volume":"68","author":"Stoyanova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2011.02.003_bib0385","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/pros.20731","article-title":"Antisense MDM2\u00a0enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo","volume":"68","author":"Mu","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.canrad.2011.02.003_bib0390","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2174\/138161210791033932","article-title":"Nutlins and ionizing radiation in cancer therapy","volume":"16","author":"Impicciatore","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.canrad.2011.02.003_bib0395","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53\u00a0regulation of thrombospondin-1","volume":"5178","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.canrad.2011.02.003_bib0400","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1535-7163.MCT-07-0442","article-title":"Nutlin-3\u00a0radiosensitizes hypoxic prostate cancer cells independent of p53","volume":"7","author":"Supiot","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2011.02.003_bib0405","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.RES.0000253975.76198.ff","article-title":"Antiangiogenic activity of the MDM2\u00a0antagonist nutlin-3","volume":"100","author":"Secchiero","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.canrad.2011.02.003_bib0410","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.bjc.6605739","article-title":"Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53","volume":"103","author":"Arya","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2011.02.003_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2009.05.008","article-title":"Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases","volume":"16","author":"Wang","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0420","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","article-title":"Mdm2\u00a0is critically and continuously required to suppress lethal p53\u00a0activity in vivo","volume":"10","author":"Ringshausen","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canrad.2011.02.003_bib0425","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.4161\/cc.8.22.10121","article-title":"Cellular quiescence caused by the Mdm2\u00a0inhibitor nutlin-3A","volume":"8","author":"Korotchnika","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canrad.2011.02.003_bib0430","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.canrad.2007.11.007","article-title":"D\u00e9terminants et facteurs pr\u00e9dictifs pour la radiosensibilit\u00e9 tumorale","volume":"12","author":"Hennequin","year":"2008","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2011.02.003_bib0435","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2009.171","article-title":"Activation of p53\u00a0by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells","volume":"23","author":"Hasegawa","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canrad.2011.02.003_bib0440","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2008.09.016","article-title":"Concomitant chemoradiotherapy in clinical trials: to promote step by step rational development","volume":"70","author":"Magn\u00e9","year":"2009","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321811000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321811000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:17:53Z","timestamp":1761135473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321811000576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1278321811000576"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2011.02.003","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciblage pharmacologique de Mdm2\u00a0: bases biologiques et perspectives de radiosensibilisation","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2011.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}